IQWiG review of Inlyta(Pfizer),Nexavar (Bayer)and Afinitor (Novartis) as treatments for Renal Cell Carcinoma

IQWiG, the German drug assessment agency,recommended that Inlyta (axitinib) from Pfizer offered considerable additional benefit in the treatment of Renal Cell Carcinoma compared to Nexavar(sorafenib) from Bayer HealthCare. However it also found that Inlyta gave no additional benefit over Afinitor (everolimus) from Novartis.

Data supporting Inlyta over Nexavar came from the AXIS study. IQWiG found no difference in outcomes as to overall survival or symptoms but Inlyta patients experienced less side effects.

Pfizer had not submitted adequate evidence supporting a comparison of Inlyta with Afinitor and IQWiG concluded that there was no additional benefit.

NICE has rejected Inlyta for NHS funding for Renal Cell Carcinoma and the comparison with Nexavar and requires a comparison with best supportive care.